MetaTOC stay on top of your field, easily

Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer

, , , , , ,

Journal of Oncology Pharmacy Practice

Published online on

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionExperts suggest doxorubicin clearance is decreased in women with a body mass index (BMI) of ≥35 kg/m2. However, few data support this recommendation.MethodsWomen receiving doxorubicin for breast cancer in three BMI groups were recruited (n = ...